Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Oncology

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

  • ID:RM00343748
  • Published: June-2016
  • Pages:2060
  • GlobalData
1 of 3

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016

Summary

The Author's clinical trial report, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-pro
Show More

1 of 3


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) 32
Jun 14, 2016: Celator Pharmaceuticals Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia 32
Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association 33
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1425 at 21st Congress of the European Hematology Association 34
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association 34
Jun 09, 2016: AbbVie Reinforces Commitment to Hematologic Oncology at 21st European Hematology Association Annual Congress Including 10 Abstracts on Investigational Medicine Venetoclax 35
Jun 08, 2016: Actinium to Present at BIO International Convention to Provide Update on Actimab-A Program 36
Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 36
Jun 06, 2016: Celator Pharmaceuticals Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS (CPX-351) Significantly Improved Overall Survival 37
Jun 06, 2016: Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting 38
Jun 06, 2016: Bio-Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016 39
Jun 06, 2016: SELLAS Life Sciences Announces Exciting Results for Galinpepimut-S, the Company's WT1 Vaccine, in Patients with Acute Myeloid Leukemia and Malignant Pleural Mesothelioma, as Presented at the 2016 ASCO Annual Meeting 39
Jun 06, 2016: Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting 41
Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers 41
Jun 01, 2016: Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial 42
May 31, 2016: Mundipharma EDO Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101 43
May 25, 2016: Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 44
May 25, 2016: GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine 45
May 24, 2016: SELLAS Life Sciences Announces Upcoming Presentation of Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting 45
May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting 46
May 19, 2016: Celator Pharmaceuticals Announces Upcoming Phase 3 Data Presentations at American Society of Clinical Oncology and European Hematology Association 47
May 19, 2016: Syros Pharmaceuticals to Present on SY-1425 at 21st Congress of the European Hematology Association 47
May 18, 2016: AbbVie To Present Data on Venclexta (venetoclax) at ASCO 2016 48
May 18, 2016: Actinium Announces Webinar to Discuss Results of the Actimab-A Phase 1 Trial and Key Findings From the HuM195-Alpha Program 48
May 16, 2016: Fate Therapeutics Announces Preclinical Data Highlighting Persistent Effector Function of Allogeneic Natural Killer Cell Cancer Immunotherapy 49
May 11, 2016: Clinical data of Medigene dendritic cell vaccines in AML presented at CIMT conference 50
May 11, 2016: Clinical data of Medigene's dendritic cell vaccines in AML presented at CIMT conference 50
May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting 51
Apr 25, 2016: Celator Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS Compared to Standard Treatment for Acute Myeloid Leukemia (AML) 51
Apr 25, 2016: GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference 52
Apr 25, 2016: Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B 52
Apr 21, 2016: Celator Pharmaceuticals to Present Phase 3 Data at 2016 American Society of Clinical Oncology Annual Meeting 53
Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia 53
Apr 19, 2016: Oncothyreon Highlights Novel Checkpoint Kinase 1 Inhibitors at American Association for Cancer Research (AACR) Annual Meeting 2016 54
Apr 18, 2016: Calithera Biosciences Announces Preclinical Presentation of CB-839 at the American Association for Cancer Research Annual Meeting 2016 54
Apr 18, 2016: Celator Pharmaceuticals Announces Data for VYXEOS in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting 55
Apr 18, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Cancer Activity of SY-1425 in Preclinical Models of Acute Myeloid Leukemia 55
Apr 18, 2016: Celator Pharmaceuticals Announces Positive Data for VYXEOS in FLT3-ITD Mutated Acute Myeloid Leukemia Cells Derived from Patients with Newly Diagnosed AML 56
Apr 18, 2016: ImmunoGen Announces Initiation of Clinical Testing of First-in-Class IMGN779 for Acute Myeloid Leukemia 56
Apr 12, 2016: UPDATE - Actinium Announces Selection of Zevacor Pharma for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial 57
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 57
Apr 01, 2016: SELLAS Life Sciences to Present Phase 2 Clinical Results for WT1 Cancer Vaccine at the 2016 ASCO Annual Meeting and the 13th International Conference of the International Mesothelioma Interest Group (iMig) 58
Clinical Trial Profile Snapshots 60
Appendix 2057
Abbreviations 2057
Definitions 2057
Research Methodology 2058
Secondary Research 2058
About The Author 2059
Contact Us 2059
Disclaimer 2059
Source 2060


List Of Tables

List of Tables
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2016* 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 9
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 13
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 14
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 15
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 16
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 19
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 22
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31


List of Figures

List of Figures
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 8
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 9
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 13
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 14
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 15
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 16
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 19
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
The Author Methodology 2058

1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.